T1	intervention 20 30	Lisinopril
T2	intervention 38 48	Carvedilol
T3	condition 60 86	Trastuzumab Cardiotoxicity
T4	eligibility 680 760	patients with HER2-positive breast cancer treated with trastuzumab for 12 months
T5	duration 783 789	2-year
T6	control 902 909	placebo
T7	No-of-participants 930 933	468
T8	average-age 945 960	51 ± 10.7 years
T9	outcome 985 999	cardiotoxicity
T10	control-value 1045 1048	32%
T11	intervention-value 1073 1076	29%
T12	intervention-value 1096 1099	30%
T13	outcome 1158 1169	event rates
T14	intervention-value 1204 1207	47%
T15	control-value 1233 1236	37%
T16	control-value 1258 1261	31%
T17	outcome 1271 1299	Cardiotoxicity-free survival
